(Q33718273)

English

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

3

object named as

Frits van Rhee

0 references

10

object named as

Bart Barlogie

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1

object named as

Sarah Waheed

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

8

object named as

Antje Hoering

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

6

object named as

Elias Anaissie

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

John D Shaughnessy

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Yazan Alsayed

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Bijay Nair

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jackie Szymonifka

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

John Crowley

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

13 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1001-1009

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023833

14 July 2018

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023833

14 July 2018

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023833

14 July 2018

Prognostic significance of copy-number alterations in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023833

14 July 2018

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023833

14 July 2018

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023833

14 July 2018

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023833

14 July 2018

The molecular classification of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023833

14 July 2018

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023833

14 July 2018

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25535

21 January 2018

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25535

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25535

21 January 2018

Individual Comparisons by Ranking Methods

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25535

21 January 2018

MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants

1 reference

https://pubmed.ncbi.nlm.nih.gov/20945320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

1 reference

https://pubmed.ncbi.nlm.nih.gov/20945320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.25535

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33718273&oldid=1963582768"